Literature DB >> 1828829

Potassium channel blockers inhibit D2 dopamine, but not A1 adenosine, receptor-mediated inhibition of striatal dopamine release.

W A Cass1, N R Zahniser.   

Abstract

D2 dopamine autoreceptors and A1 adenosine heteroreceptors inhibit the evoked release of dopamine from rat striatum. We examined the role of potassium channels in this modulation by determining the effects of two potassium channel blockers, 4-aminopyridine and tetraethylammonium, on the modulation of electrically stimulated release of endogenous dopamine from rat striatal slices. Maximally effective concentrations of the D2 dopamine receptor agonist N-0437 (10 nM) and of adenosine (50 microM) caused a 30% inhibition of evoked dopamine overflow, and their effects were additive. When coperfused with N-0437, both 4-aminopyridine and tetraethylammonium blocked the inhibition caused by N-0437 in a dose-dependent manner. 4-Aminopyridine was approximately three orders of magnitude more potent than tetraethylammonium, with complete blockade occurring at 3 microM and 1 mM, respectively. Binding experiments confirmed that neither 4-aminopyridine nor tetraethylammonium was a direct-acting D2 dopamine receptor antagonist at the concentration necessary to block the release-modulatory effect of D2 receptor activation. In contrast, the inhibitory modulation produced by adenosine was not affected by 4-aminopyridine (30 microM) or tetraethylammonium (1 mM). These results suggest that D2 dopamine and A1 adenosine receptors inhibit dopamine release in the striatum by different mechanisms. D2 dopamine autoreceptor action appears to involve potassium channels, whereas A1 adenosine receptor action does not.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828829     DOI: 10.1111/j.1471-4159.1991.tb02109.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

2.  Contribution of Kv1.2 voltage-gated potassium channel to D2 autoreceptor regulation of axonal dopamine overflow.

Authors:  Stephanie Fulton; Dominic Thibault; Jose A Mendez; Nicolas Lahaie; Emanuele Tirotta; Emiliana Borrelli; Michel Bouvier; Bruce L Tempel; Louis-Eric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

3.  Influences of different adenosine receptor subtypes on catalepsy in mice.

Authors:  M R Zarrindast; M Modabber; M Sabetkasai
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Ether-à-go-go 1 (Eag1) potassium channel expression in dopaminergic neurons of basal ganglia is modulated by 6-hydroxydopamine lesion.

Authors:  N R Ferreira; M Mitkovski; W Stühmer; L A Pardo; E A Del Bel
Journal:  Neurotox Res       Date:  2011-11-03       Impact factor: 3.911

5.  Protein kinase C beta regulates the D₂-like dopamine autoreceptor.

Authors:  Kathryn D Luderman; Rong Chen; Mark J Ferris; Sara R Jones; Margaret E Gnegy
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

6.  Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors.

Authors:  Hui Zhang; David Sulzer
Journal:  Basal Ganglia       Date:  2012-03-01

Review 7.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

8.  Dendrotoxin blocks a class of potassium channels that are opened by inhibitory presynaptic modulators in rat cortical synaptosomes and slices.

Authors:  G Zoltay; J R Cooper
Journal:  Cell Mol Neurobiol       Date:  1993-02       Impact factor: 5.046

9.  Role of ATP-sensitive K+ channels in antinociception induced by R-PIA, an adenosine A1 receptor agonist.

Authors:  M Ocaña; J M Baeyens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

Review 10.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.